EGRX
$58.37
Eagle Pharmaceuticals
($.60)
(1.02%)
EGRX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.07
Revenue:  $44.50 Mil
Thursday
Feb 27
6:50 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 12, 2019

What do you expect when EGRX reports earnings?
Beat
Meet
Miss

Where is EGRX's stock price going from here?
Up
Flat
Down
Stock chart of EGRX
Analysts
Summary of analysts' recommendations for EGRX
Score
Grade
Pivots
Resistance
$60.55
$60.02
$59.20

$58.67

Support
$57.85
$57.32
$56.50
Tweet
Growth
Description
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
Peers
Regeneron PharmaceuticalsInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalMylanZoetisJohnson & JohnsonUltragenyx PharmaceuticalEndo International plcBristol-Myers Squibb
›